CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like First international consensus unifies fasting terminology to boost global research July 28, 2024 Extreme heat alert: Understanding the impact of heatwaves on public health July 19, 2024 Discovery of leptin-responsive neurons offers new hope for obesity treatment December 5, 2024